Same™ by i-SEP medical device has obtained the CE mark and started marketing

19 September 2022

i-SEP announces the CE marking and marketing of its autotransfusion medical device: same™ by i-SEP. For the past several months I-SEP has been preparing to market its highly innovative and unique autotransfusion system in the sector by intensifying its presence at scientific congresses such as NATA or ARCOTHOVA and presenting its unique autotransfusion system in European hospitals confirming the interest and support of the scientific community. Obtaining the CE mark represents a major step in the company’s development and means this process can continue with the start of marketing the same™ blood recovery device to European hospitals and clinics.

  • Obtaining the CE mark according to the requirements of the new European regulation MDR 2017/745 for its unique and innovative intraoperative Blood Recovery Technology (RSPO) capable of recovering both red blood cells and platelets for the benefit of patients: same™ by I-SEP.
  • This major step allows i-SEP to start marketing its patented technology in Europe; the first centres have already expressed their wish to acquire this device, which responds to the major public health issue of better blood management.
  • i-SEP’s goal: become the first company to market an autotransfusion system that can recover both red blood cells and platelets during bleeding surgical procedures, with ergonomic and intuitive equipment and with a treatment time compatible with surgical practice.

⭐️ same™ by I-SEP is the 1st and only intraoperative autotransfusion technology capable of preserving platelets in addition to the patient’s red blood cells.